항바이러스제 : 시장 인사이트, 역학, 시장 예측(2030년)

Antiviral Drugs Market by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors, and Others), Indication (HIV Infection, Herpes, Hepatitis, Influenza, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of various infectious diseases such as influenza, HIV, hepatitis, and others and the increasing initiatives to curb the viral diseases by public and private companies across the globe

The antiviral drugs market will grow at a CAGR of 3.65% during the forecast period from 2024 to 2030 to reach USD 51,466.21 million by 2030. The antiviral drugs market is growing significantly due to the increasing prevalence of viral diseases like HIV, hepatitis, and ebola. Rising awareness initiatives, an expanding geriatric population, and advancements in drug efficacy, such as proteolysis targeting chimera and targeted covalent inhibitors, further drive the market demand. Additionally, increased research and development, along with more drug approvals and launches, and the presence of key market players, are boosting the market growth. Consequently, the antiviral drugs market is expected to grow substantially from 2024 to 2030.

Antiviral Drugs Market Dynamics:

As per the World Health Organization (WHO) 2024, nearly 39 million people were living with HIV infection in 2022, globally. The source also stated that nearly 37.5 million were adults (aged 15 and above) and approximately 1.5 million people were children, aged less than 15 years.

The source UNAIDS 2022 report stated that nearly 1.5 million people became newly infected with HIV infection, in 2021, globally. The source also mentioned that in 2021, 28.7 million people were accessing antiretroviral therapy, globally. These statistics illustrate the persistent and widespread impact of HIV, necessitating continued and enhanced efforts in antiviral drug development. The high prevalence of HIV, coupled with the substantial number of new infections each year, drives the demand for effective antiviral treatments. Therefore the market for antiviral drugs is expected to grow in the upcoming years.

Additionally, the growing research and developmental activities, expanding product launches and approvals around the world, presence of a robust number of drugs in the pipeline, and strategic activities by the key players to increase the manufacturing and research for the anti-viral drugs will in turn bolster the market. For instance, in April 2021, Atriva Therapeutics GmbH, a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies received EUR 11.4 million in federal funding.

Furthermore, advances in molecular biology are promoting drug development with the growing use of nucleoside and nucleotide analogs as first-line antivirals. According to the market's current development pipeline, many small molecule-based antiviral drugs are expected to receive product approvals, propelling market growth to unprecedented heights during the forecast period.

Therefore, the factors stated above collectively will drive the overall antiviral drugs market during the forecast period from 2024 to 2030.

However, the emergence of antiviral drug resistance, side effects associated with antiviral drugs, and the timeline of the stringent regulatory approval process may prove to be challenging factors for antiviral drug market growth.

Antiviral Drugs Market Segment Analysis:

Antiviral Drugs Market by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors, and Others), Indication (HIV Infection, Herpes, Hepatitis, Influenza, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the indication segment of the antiviral drugs market, the influenza category is expected to have a significant revenue share in the year 2023. This is primarily owing to the rising demand and availability of antiviral drugs in the market owing to the increasing prevalence of various viral diseases, expanding launches and strategic investments and other activities relating to antiviral drugs by key players in the market, and wide application and advantages offered by the segment.

As per the WHO Virological Surveillance Summary 2022, from week 1, 2022 to week 44, 2022, nearly 54,051 of 418,329 were found positive for an influenza virus in China. The enlarged diagnosis of influenza across various regions across the globe is expected to affect the market optimistically, as more patients will reach out for antiviral therapies after being diagnosed.

Furthermore, surging research and developmental activities, drug launches and approvals, the presence of a robust number of influenza-treating antiviral drugs in the pipeline, and other factors will create a productive opportunity for market growth during the upcoming years. For instance, in November 2021, Seqirus, a global leader in influenza, announced that the U.S. Food and Drug Administration (FDA) had granted supplemental approval of a multi-dose vial (MDV) formulation of AUDENZ(TM) (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvant, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A (H5N1) in the event of a pandemic.

Therefore, owing to the above-mentioned factors, the demand for influenza drugs upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the antiviral drugs market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall antiviral drugs market:

Among all the regions, North America is expected to dominate the antiviral drugs market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030.

This can be ascribed to the increasing demand for antiviral drugs in the region owing to the growing prevalence of many viral and infectious diseases, the increasing geriatric population suffering from viral diseases, the growing initiatives for the awareness of viral diseases, the launch of new drugs, the presence of key market players in the region, and others are among the key factors that contribute to the growth of the antiviral drugs market in North America.

According to the Centers for Disease Control and Prevention (2023), in 2021 approximately 1.2 million people had HIV infections in the US. Furthermore, according to the latest study conducted by the U.S. Department of Health & Human Services, approximately 2.4 million people were estimated to be living with hepatitis C in the United States and nearly 850,000 people in the US were estimated to be living with hepatitis B, in 2021. This underscores the continuous need for effective antiviral therapies. Additionally, healthcare initiatives and government support aimed at addressing these viral infections further emphasize the market's expansion potential for antiviral drugs.

Increased positive results in various antiviral drugs also strive for the overall market of antiviral drugs. For example in October 2023, Johnson & Johnson; a leading manufacturing company in the US, announced the promising data from a Phase 2a human challenge study evaluating JNJ-1802. A first in class oral antiviral in development for the prevention of dengue. The data showed that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo, and is safe as well as well tolerated.

Additionally, to upsurge the market growth of antiviral drugs, the federal government is providing support funds to pharmaceutical companies to help them strengthen their clinical development pipelines. For instance, the Centers for Disease Control and Prevention (CDC) allocates funds through grants to support research into hepatitis prevention and treatment strategies. Pharmaceutical companies often collaborate with CDC-funded researchers to develop new antiviral therapies for hepatitis B and hepatitis C.

Furthermore, the presence of sophisticated healthcare infrastructure and high awareness among end users such as clinicians and healthcare professionals are estimated to be the key growth drivers. Also, the presence of favorable reimbursement policies is anticipated to further fuel North America's antiviral drugs market during the forecast period from 2024 to 2030

Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America region in the antiviral drugs market.

Antiviral Drugs Market key players:

Some of the key market players operating in the Antiviral Drugs market include AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Cipla Inc., Lupin., ENTOD INTERNATIONAL, AstraZeneca, Dr. Reddy's Laboratories Ltd., GSK plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Sanofi, ViiV Healthcare, Aurobindo Pharma., Sun Pharmaceutical Industries Ltd., Viatris Inc., Boehringer Ingelheim, and others.

Recent Developmental Activities in the Antiviral Drugs Market:

• In January 2022, ENTOD Pharmaceuticals launched MOLENTOD in India. The product will be available at retail chemists, pharmacy chains, hospitals, and online stores at an affordable price.
• In December 2021, the U.S. Food and Drug Administration (FDA) granted an emergency use authorization (EUA) to molnupiravir for use in certain populations where other treatments are not feasible.

Key Takeaways from the Antiviral Drugs Market Report Study

• Market size analysis for current antiviral drugs market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the antiviral drugs market.
• Various opportunities available for the other competitors in the antiviral drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current antiviral drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for antiviral drugs market growth in the coming future?

Target audience who can be benefited from this Antiviral Drugs Market Report Study

• Antiviral drug product providers
• Research organizations and consulting companies
• Antiviral drugs-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in antiviral drugs
• Various end users who want to know more about the antiviral drugs market and the latest developments in the antiviral drugs market.

Frequently Asked Questions for the Antiviral Drugs Market:

1. What are antiviral drugs?

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses.

2. What is the market for antiviral drugs?

The antiviral drugs market will grow at a CAGR of 3.65% during the forecast period from 2024 to 2030 to reach USD 51,466.21 million by 2030.

3. What are the drivers for the antiviral drugs market?

The antiviral drugs market is growing significantly due to the increasing prevalence of viral diseases like HIV, hepatitis, and Ebola. Rising awareness initiatives, an expanding geriatric population, and advancements in drug efficacy, such as proteolysis targeting chimera and targeted covalent inhibitors, further drive demand. Additionally, increased research and development, along with more drug approvals and launches, and the presence of key market players, are boosting market growth. Consequently, the antiviral drugs market is expected to grow substantially from 2024 to 2030.

4. Who are the key players operating in the antiviral drugs market?

Some of the key market players operating in the antiviral drugs market include AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Cipla Inc., Lupin., ENTOD INTERNATIONAL, AstraZeneca, Dr. Reddy's Laboratories Ltd., GSK plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Sanofi, ViiV Healthcare, Aurobindo Pharma., Sun Pharmaceutical Industries Ltd., Viatris Inc., Boehringer Ingelheim, and others.

5. Which region has the highest share in the antiviral drugs market?

Among all the regions, North America is estimated to hold a significant revenue share in the antiviral drugs market. This can be ascribed to the increasing demand for antiviral drugs among the patients in the region owing to the increasing prevalence of HIV, hepatitis, and other viral diseases. Further, the growing initiatives for the awareness of viral diseases, the increasing geriatric population base prone to viral diseases, and the presence of key domicile players in the region are the reasons that act as a supportive factor for the North America antiviral drugs market growth during the forecast period from 2024 to 2030.

Table of Contents

1. Antiviral Drugs Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Antiviral Drugs Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Antiviral Drugs Market Key Factors Analysis

• 5.1. Antiviral Drugs Market Drivers
  • 5.1.1. Growing prevalence of various infectious diseases such as HIV, Herpes, Influenza, and others
  • 5.1.2. Growing initiatives for the awareness of infectious diseases
  • 5.1.3. Increasing geriatric population base prone to various infectious diseases such as Influenza, Hepatitis
  • 5.1.4. Rising strategic steps by the key players for the development and manufacturing of antiviral drugs
• 5.2. Antiviral Drugs Market Restraints and Challenges
  • 5.2.1. The emergence of antiviral drugs resistance
  • 5.2.2. Side effects associated with the antiviral drug
  • 5.2.3. The timeline of the stringent regulatory approval
• 5.3. Antiviral Drugs Market Opportunities
  • 5.3.1. Increasing approval and expected commercialization of novel medicines for viral infections

6. Antiviral Drugs Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Antiviral Drugs Market Assessment

• 7.1. By Drug Class
  • 7.1.1. DNA Polymerase Inhibitors
  • 7.1.2. Reverse Transcriptase Inhibitors
  • 7.1.3. Neuraminidase Inhibitors
  • 7.1.4. Protease Inhibitors
  • 7.1.5. Others
• 7.2. By Indication
  • 7.2.1. HIV Infection
  • 7.2.2. Herpes
  • 7.2.3. Hepatitis
  • 7.2.4. Influenza
  • 7.2.5. Others
• 7.3. By Distribution Channel
  • 7.3.1. Hospital Pharmacy
  • 7.3.2. Retail Pharmacy
  • 7.3.3. E-commerce
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.1.2. Canada Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.1.3. Mexico Antiviral Drugs Market Size in USD million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.2.2. Germany Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.2.4. Italy Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.2.5. Spain Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Antiviral Drugs Market Size in USD million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.3.2. Japan Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.3.3. India Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.3.4. Australia Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.3.5. South Korea Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia-Pacific Antiviral Drugs Market Size in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.4.2. Africa Antiviral Drugs Market Size in USD million (2021-2030)
    • 7.4.4.3. South America Antiviral Drugs Market Size in USD million (2021-2030)

8. Antiviral Drugs Market Company and Product Profiles

• 8.1. AbbVie Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Bristol-Myers Squibb Company
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Gilead Sciences, Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Hoffmann-La Roche Ltd
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Pfizer Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Cipla Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Lupin.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. ENTOD INTERNATIONAL
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. AstraZeneca
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Reddy's Laboratories Ltd.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. GSK plc.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Johnson & Johnson
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Merck & Co., Inc.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Novartis AG
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Sanofi
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. ViiV Healthcare
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Aurobindo Pharma.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Sun Pharmaceutical Industries Ltd.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Viatris Inc.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Boehringer Ingelheim
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us